



<p><b>Human Subjects?</b> If yes, indicate "Pending", IRB # or Exemption #: <span style="float: right;">Delayed Onset</span></p> <p><b>NIH-funded Clinical Trial?</b> If yes, investigators and staff involved in the conduct, oversight, or management of clinical trials should be trained in <a href="#">Good Clinical Practice</a>. Training is available through <a href="#">CITI Program</a>. Additional information about <a href="#">NIH-funded Clinical Trials</a> can be found on the <a href="#">NIH website</a>. Provide names on the next page.</p> <p><b>Will the clinical research study utilize UCLA Health System resources, including but not limited to, any patient care costs? If yes, then a Policy 915 Coverage Analysis is required (contact <a href="mailto:coverageanalysis@mednet.ucla.edu">coverageanalysis@mednet.ucla.edu</a>).</b></p> <p><b>Animal Subjects?</b> If yes, indicate "Pending" or ARC#: <span style="float: right;">Delayed Onset</span></p> <p><b>Use of radiation in animals and/or humans?</b> If yes, indicate "Pending," MRSC/RDRC # and/or RUA #:  Pending MRSC/RDRC #: _____ RUA #: _____</p> <p><b>Human Pluripotent Stem Cell Research (including embryonic stem cells, induced pluripotent stem cells, and/or their derivatives)?</b> Visit <a href="https://stemcell.ucla.edu/oversight-review">https://stemcell.ucla.edu/oversight-review</a> for more information.</p> <p><b>Non-UCLA materials/equipment to be used?</b> If yes, indicate type: _____ Source: _____</p> <p><b>Human or primate cells, tissue, or fluids; recombinant or synthetic nucleic acids; potentially infectious materials; exotic plants or plant pathogens; select agents or toxins?</b> For more information, see <a href="#">IBC website</a>.</p> <p><b>Use of UC IP?</b> If yes, specify case number: _____</p>		
Yes	No	<p><b>Export Control (see <a href="#">RPC Website</a>) – Does the project involve the following:</b></p> <p><b>Shipping or carrying any tangible object or item to a foreign country?</b> If yes, specify: _____</p> <p><b>Conducting research or other activities in, taking money to or planning to have money transferred to a foreign country?</b> If yes, specify: _____</p> <p><b>Training foreign persons in using equipment, technology, or technical data?</b> If yes, specify: _____</p> <p><b>Traveling to or doing research in a country currently under a US Trade or Economic Embargo (See <a href="#">OFAC Website</a>)?</b> If yes, specify: _____</p>

**7. Additional Forms Required**

Yes	No	<p><b>COI (<a href="#">Disclosure Requirements</a>)</b></p> <p><b>Sponsor/Prime Sponsor is Federal <a href="#">Public Health Service (PHS)</a>, <a href="#">agency that has adopted the PHS regulations</a>, or <a href="#">Department of Energy</a>?</b> If yes, provide names of other investigators on <a href="#">page 3 (See UCLA Policies 926 and 927)</a></p> <p><b>Sponsor/Prime Sponsor is Federal (other than PHS), <a href="#">CIRM</a> or special research programs managed by the UC Research Grants Program Office (<a href="#">RGPO</a>)?</b> If yes, attach COI <a href="#">Form 740 &amp; Supplement to Form 740</a> (if applicable). See <a href="#">UCLA Procedure 925.3</a>.</p> <p><b>Non-Government Sponsor/Prime Sponsor?</b> If yes and project is <i>Research</i>, attach <a href="#">Form 700-U</a>, <a href="#">700-U Addendum</a> and <a href="#">700-U Supplement</a>, as applicable, unless sponsor is <i>exempt</i>. See <a href="#">UCLA Procedure 925.2</a></p>
Yes	No	<p><b>Industry Sponsored Research</b></p> <p><b>Industry Sponsored Non-Clinical Trial Proposal?</b> If yes, attach <a href="#">Industry Sponsored Research Checklist</a>.</p> <p><b>Industry Sponsored Clinical Trial?</b> If yes, view the <a href="#">Clinical Trials Contracts &amp; Strategic Relations Checklist</a> to determine additional required attachments.</p>

**8. Funds Requested**

**1st Budget Period**

Direct Costs (\$): \_\_\_\_\_ Excluded Direct Costs (\$): \_\_\_\_\_ F&A Costs (\$): \_\_\_\_\_ Total Costs (\$): \_\_\_\_\_

**All Project Periods** (*complete only when multiple budget periods are involved*)

Direct Costs (\$): \_\_\_\_\_ Excluded Direct Costs (\$): \_\_\_\_\_ F&A Costs (\$): \_\_\_\_\_ Total Costs (\$): \_\_\_\_\_

**F&A:** F&A Rate (%): \_\_\_\_\_ F&A Base Type: \_\_\_\_\_ If Other, specify: \_\_\_\_\_

**9. Remarks**

**10. Accepts Responsibility**

**Approvals: Includes Certifications**

*The Investigator(s) certifies to the following: (1) that the information submitted within this application is true, complete and accurate to the best of their knowledge; (2) that any false, fictitious, or fraudulent statements or claims may subject the Investigator(s) to criminal, civil or administrative penalties; (3) agrees to accept responsibility for the scientific conduct of the project and to provide the required progress reports if a grant is awarded as a result of the application; and (4) that you are not currently debarred, suspended or ineligible to receive federal or non-federal funds; (5) all Clinical Trials based upon [FDAAA 801](#), will be registered in [ClinicalTrials.gov](#). When multiple Investigators are proposed in an application this assurance must be obtained by all named Investigators.*

\_\_\_\_\_  
Principal Investigator (Required) Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Chair/ORU Director/Dean/Medical Center Director (Required) Date

\_\_\_\_\_  
Date

\_\_\_\_\_  
Date

For proposal submissions funded by [Federal Public Health Service \(PHS\)](#), an agency that has adopted the PHS regulations, or Department of Energy (DOE), provide the name and email address for all project personnel responsible for the purpose\*, design, conduct, or reporting of research. All named individuals must have a current disclosure in eDGE, which can be accessed at [coi.research.ucla.edu](http://coi.research.ucla.edu).

**No other project personnel responsible for the purpose\*, design, conduct, or reporting of research.**

\*The term purpose is an addition to the definition by DOE only.

First Name	M.I.	Last Name	Email Address	eDGE Disclosure Date

Investigators and staff involved in the conduct, oversight, or management of clinical trials should be trained in [Good Clinical Practice](#). Training is available through [CITI Program](#). Additional information about NIH-funded Clinical Trials can be found on the [NIH website](#). Provide the names on the table below.

**No other investigators or staff involved in the conduct, oversight, or management of NIH-funded clinical trials.**

First Name	M.I.	Last Name	Email Address	GCP Training Completion Date

You have selected a sponsor and/or prime sponsor that requires completion of [Research Security Training](#). All Senior/Key Personnel (NSF) or Covered Individuals (DOE) are required to fulfill this training requirement prior to proposal submission. See OCGA's Sponsor Specific Guidance for more information: [Sponsor Specific Guidance](#)

**No other investigators or staff are required to complete the Research Security Training**

First Name	M.I.	Last Name	Email Address	Res. Sec. Training Completion Date